Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
<p>Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to...
Saved in:
Main Authors: | Amany R Keruakous (Author), Silas Day (Author), Carrie Yuen (Author) |
---|---|
Format: | Book |
Published: |
Global Journal of Cancer Therapy - Peertechz Publications,
2021-02-13.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiple Myeloma
Published: (2021) -
Multiple Myeloma An Overview
Published: (2012) -
Update on Multiple Myeloma
Published: (2019) -
Immunotherapy in Multiple Myeloma
Published: (2019) -
Multiple Myeloma A Quick Reflection on the Fast Progress
Published: (2013)